Home NKGEN Biotech

NKGEN Biotech

acquired
Post-IPO Round
Cellular Immunotherapy Drug Developer
Basic
Enterprise Profile

Basic Information

NKGen Biotech is a clinical-stage biotechnology company focused on developing and commercializing innovative autologous, allogeneic, and CAR-NK natural killer cell therapies using our proprietary SNK (Supercharged Natural Killer) platform. Leading our industry-disrupting technology are our senior leadership, senior advisors, and management team, who together bring extensive knowledge and expertise in the field of immuno-oncology, and are passionate and excited about our work to enhance the immune system.
NKGEN Biotech, Inc.
California,United States of America
15~50 people
January 01, 2017
info@nkgenbiotech.com

Enterprise Profile

Industrial Sector
New Drug Development Immune Cell Therapy
Technology
Gene Technology Cell Technology
Concept
Dermatology Department Immune System Diseases Skin Diseases Therapeutic Products Lung Cancer
Application Scenarios
Biologics Innovative Drugs